Bosnalijek expands business in Libya
This article was originally published in Scrip
The main manufacturer of generic pharmaceuticals in Bosnia and Herzegovina, Bosnalijek, is extending its co-operation with Libya. The Libyan government has astake of around 10% in the company and is its third-largest shareholder (Scrip Online, March 7th, 2008).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.